Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion INCHEON, Korea — Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026…
Read More
About The Author
